nimodipine has been researched along with Cerebral Microangiopathies in 3 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "CONIVaD (choline alphoscerate and nimodipine in vascular dementia) is a pilot, single-center, double-blinded, randomized trial aimed to assess whether the association of choline alphoscerate and nimodipine is more effective than nimodipine alone in reducing cognitive decline in patients with SVD and mild-to-moderate cognitive impairment." | 5.34 | Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2020) |
| " Fourteen patients (22%) dropped out for reasons including consent withdrawal (n = 9), adverse reactions (n = 4), and stroke (n = 1)." | 3.01 | Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2021) |
| " In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group." | 1.51 | Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. ( Liu, N; Yang, C; Zhang, J, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Salvadori, E | 2 |
| Poggesi, A | 2 |
| Donnini, I | 2 |
| Rinnoci, V | 2 |
| Chiti, G | 2 |
| Squitieri, M | 2 |
| Tudisco, L | 2 |
| Fierini, F | 2 |
| Melone, A | 2 |
| Pescini, F | 2 |
| Pantoni, L | 2 |
| Zhang, J | 1 |
| Liu, N | 1 |
| Yang, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment[NCT03228498] | Phase 2 | 62 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for nimodipine and Cerebral Microangiopathies
| Article | Year |
|---|---|
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Topics: Aged; Aged, 80 and over; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Glycerylphosphorylch | 2021 |
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Topics: Aged; Calcium Channel Blockers; Cerebral Small Vessel Diseases; Cognitive Dysfunction; Dementia, Vas | 2020 |
1 other study available for nimodipine and Cerebral Microangiopathies
| Article | Year |
|---|---|
Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease.
Topics: Activities of Daily Living; Aged; C-Reactive Protein; Cerebral Small Vessel Diseases; Cholesterol; C | 2019 |